The possibilities of using sodium-glucose cotransporter type 2 inhibitors in the treatment of patients with cardiovascular diseases (literature review)

Abstract

Myocardial infarction remains one of the most common causes of chronic heart failure. Modern innovative treatment of patients with high cardiovascular risk is the use of sodium-glucose cotransporter type 2 inhibitors - a class of antidiabetic drugs. This review is devoted to the study of dapagliflozin and empagliflozin effect on the quality of life and prognosis in patients with myocardial infarction and chronic heart failure. Special attention in the review is paid to the analysis of some pleiotropic effects of drugs in clinical studies of patients with various variants of coronary heart disease, as well as in experimental studies on animals. The systematic review was carried out in accordance with the recommendations and reporting provisions for Systematic Reviews and Meta-analyses (PRISMA). The search was conducted in PubMed electronic databases, elibrary.ru without restrictions on the date of publication of publications. The last search was carried out on August 12, 2023.

Keywords

• myocardial infarction
• chronic heart failure
• empagliflozin
• dapagliflozin
• quality of life
• cardiovascular prognosis